Scholarlink

Background <p>Evidence regarding a preventive impact of antiviral medication for influenza on hospitalization or mortality among non-severe cases is scarce. The objective of this study was to assess the association between the use of antiviral medications in non-hospitalized patients with influenza and their subsequent hospitalization and mortality.</p> Methods <p>This multi-center retrospective cohort study used TriNetX, a global database to assess the clinical impact of antiviral medications (oseltamivir, laninamivir, zanamivir, peramivir, and baloxavir) for influenza among non-hospitalized patients. The outcomes included hospitalization, emergency department visit, intensive care unit (ICU) admission, and mortality between 3 and 30&#xa0;days following influenza diagnosis with the 2-day window period between diagnosis and antiviral administration. Propensity score matching with a 1:1 ratio was conducted to estimate the risk ratio (RR).</p> Results <p>A total of 1,016,581 patients with influenza were identified. After matching, 426,275 patients from each cohort were compared. The antiviral-treated group was associated with lower risks of hospitalization (RR 0.91; 95% confidence interval 0.85–0.95; <i>p</i> &lt; 0.001); emergency department visits (RR 0.80; 95% CI 0.79–0.82; <i>p</i> &lt; 0.001), ICU admission (RR 0.84; 95% CI 0.73–0.97; <i>p</i> = 0.016); and mortality (RR 0.60; 95% CI 0.47–0.77; <i>p</i> &lt; 0.001). The sensitivity analysis revealed that the statistical significance in hospitalization was maintained by replacing the 2-day window period with 0&#xa0;days (RR 0.82; 95% CI 0.79–0.84; <i>p</i> &lt; 0.001). The sensitivity analysis limited to those aged 2 to 64&#xa0;years without any high-risk comorbidities in the antiviral-treated group compared to the antiviral-untreated group showed fewer outcome events for hospitalization (RR 0.76; 95% CI 0.68–0.85; <i>p</i> &lt; 0.001); ED visit (RR 0.68; 95% CI 0.65–0.71; <i>p</i> &lt; 0.001); and ICU admission (RR 0.48; 95% CI 0.30–0.78; <i>p</i> = 0.002).</p> Conclusions <p>Antiviral treatment was negatively associated with hospitalization, ICU admission, and mortality. The results need to be interpreted with caution, given limitations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of antiviral use for influenza among non-severe cases with subsequent hospitalization and mortality

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月6日

查看全文
  • Taito Kitano,
  • Shinya Tsuzuki,
  • Sayaka Yoshida

摘要

Background

Evidence regarding a preventive impact of antiviral medication for influenza on hospitalization or mortality among non-severe cases is scarce. The objective of this study was to assess the association between the use of antiviral medications in non-hospitalized patients with influenza and their subsequent hospitalization and mortality.

Methods

This multi-center retrospective cohort study used TriNetX, a global database to assess the clinical impact of antiviral medications (oseltamivir, laninamivir, zanamivir, peramivir, and baloxavir) for influenza among non-hospitalized patients. The outcomes included hospitalization, emergency department visit, intensive care unit (ICU) admission, and mortality between 3 and 30 days following influenza diagnosis with the 2-day window period between diagnosis and antiviral administration. Propensity score matching with a 1:1 ratio was conducted to estimate the risk ratio (RR).

Results

A total of 1,016,581 patients with influenza were identified. After matching, 426,275 patients from each cohort were compared. The antiviral-treated group was associated with lower risks of hospitalization (RR 0.91; 95% confidence interval 0.85–0.95; p < 0.001); emergency department visits (RR 0.80; 95% CI 0.79–0.82; p < 0.001), ICU admission (RR 0.84; 95% CI 0.73–0.97; p = 0.016); and mortality (RR 0.60; 95% CI 0.47–0.77; p < 0.001). The sensitivity analysis revealed that the statistical significance in hospitalization was maintained by replacing the 2-day window period with 0 days (RR 0.82; 95% CI 0.79–0.84; p < 0.001). The sensitivity analysis limited to those aged 2 to 64 years without any high-risk comorbidities in the antiviral-treated group compared to the antiviral-untreated group showed fewer outcome events for hospitalization (RR 0.76; 95% CI 0.68–0.85; p < 0.001); ED visit (RR 0.68; 95% CI 0.65–0.71; p < 0.001); and ICU admission (RR 0.48; 95% CI 0.30–0.78; p = 0.002).

Conclusions

Antiviral treatment was negatively associated with hospitalization, ICU admission, and mortality. The results need to be interpreted with caution, given limitations.